The Business Times
SUBSCRIBERS

GIC backs Esco Lifesciences in oversubscribed US$200m Series A round

Published Thu, May 27, 2021 · 09:00 AM

SINGAPORE-BASED Esco Lifesciences, which supplies life sciences tools for the healthcare industry, has raised US$200 million in an oversubscribed Series A round, as it seeks to expedite expansion in China, and hunt down acquisitions worldwide.

The company is preparing to go public in Hong Kong in the coming months, according to a person familiar with the matter, after its latest round valued it at over US$800 million following the fundraising.

The fundraising, also billed as its crossover round, was led by US-based healthcare investment firm Vivo Capital and Denmark-based life science investor Novo Holdings, the venture arm of Novo Nordisk Foundation.

KEYWORDS IN THIS ARTICLE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Startups

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here